220 related articles for article (PubMed ID: 30196066)
21. Role of triptolide as an adjunct chemotherapy for ovarian cancer.
Westfall SD; Nilsson EE; Skinner MK
Chemotherapy; 2008; 54(1):67-76. PubMed ID: 18073474
[TBL] [Abstract][Full Text] [Related]
22. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
23. Activation of Nrf2 protects against triptolide-induced hepatotoxicity.
Li J; Shen F; Guan C; Wang W; Sun X; Fu X; Huang M; Jin J; Huang Z
PLoS One; 2014; 9(7):e100685. PubMed ID: 24988078
[TBL] [Abstract][Full Text] [Related]
24. 3-O-(Z)-coumaroyloleanolic acid overcomes Cks1b-induced chemoresistance in lung cancer by inhibiting Hsp90 and MEK pathways.
Wang H; Sun M; Guo J; Ma L; Jiang H; Gu L; Wen H; Liao S; Chen J; Zeng B; Li Y; Li Y; Yu X; Feng Y; Zhou Y
Biochem Pharmacol; 2017 Jul; 135():35-49. PubMed ID: 28288818
[TBL] [Abstract][Full Text] [Related]
25. Carboxyamidotriazole Synergizes with Sorafenib to Combat Non-Small Cell Lung Cancer through Inhibition of NANOG and Aggravation of Apoptosis.
Chen C; Ju R; Shi J; Chen W; Sun F; Zhu L; Li J; Zhang D; Ye C; Guo L
J Pharmacol Exp Ther; 2017 Aug; 362(2):219-229. PubMed ID: 28515157
[TBL] [Abstract][Full Text] [Related]
26. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.
Solis LM; Behrens C; Dong W; Suraokar M; Ozburn NC; Moran CA; Corvalan AH; Biswal S; Swisher SG; Bekele BN; Minna JD; Stewart DJ; Wistuba II
Clin Cancer Res; 2010 Jul; 16(14):3743-53. PubMed ID: 20534738
[TBL] [Abstract][Full Text] [Related]
27. Synergistic anticancer activity of triptolide combined with cisplatin enhances apoptosis in gastric cancer in vitro and in vivo.
Li CJ; Chu CY; Huang LH; Wang MH; Sheu LF; Yeh JI; Hsu HY
Cancer Lett; 2012 Jun; 319(2):203-213. PubMed ID: 22306340
[TBL] [Abstract][Full Text] [Related]
28. An overview of chemical inhibitors of the Nrf2-ARE signaling pathway and their potential applications in cancer therapy.
Zhu J; Wang H; Chen F; Fu J; Xu Y; Hou Y; Kou HH; Zhai C; Nelson MB; Zhang Q; Andersen ME; Pi J
Free Radic Biol Med; 2016 Oct; 99():544-556. PubMed ID: 27634172
[TBL] [Abstract][Full Text] [Related]
29. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
30. Triptolide suppresses the in vitro and in vivo growth of lung cancer cells by targeting hyaluronan-CD44/RHAMM signaling.
Song JM; Molla K; Anandharaj A; Cornax I; O Sullivan MG; Kirtane AR; Panyam J; Kassie F
Oncotarget; 2017 Apr; 8(16):26927-26940. PubMed ID: 28460475
[TBL] [Abstract][Full Text] [Related]
31. Flumethasone enhances the efficacy of chemotherapeutic drugs in lung cancer by inhibiting Nrf2 signaling pathway.
Zhou Y; Zhou Y; Wang K; Li T; Yang M; Wang R; Chen Y; Cao M; Hu R
Cancer Lett; 2020 Apr; 474():94-105. PubMed ID: 31954771
[TBL] [Abstract][Full Text] [Related]
32. PAQR4 promotes chemoresistance in non-small cell lung cancer through inhibiting Nrf2 protein degradation.
Xu P; Jiang L; Yang Y; Wu M; Liu B; Shi Y; Shen Q; Jiang X; He Y; Cheng D; Xiong Q; Yang Z; Duan L; Lin J; Zhao S; Shi P; Yang C; Chen Y
Theranostics; 2020; 10(8):3767-3778. PubMed ID: 32206121
[No Abstract] [Full Text] [Related]
33. Nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) in non-small cell lung cancer.
Zeng Z; Wang ZY; Li YK; Ye DM; Zeng J; Hu JL; Chen PF; Xiao J; Zou J; Li ZH
Life Sci; 2020 Aug; 254():117325. PubMed ID: 31954159
[TBL] [Abstract][Full Text] [Related]
34. Herbal compound triptolide synergistically enhanced antitumor activity of vasostatin120-180.
Lin Y; Yang X; Lu M; Zheng W; Zhang J; Zhuang H; Hua ZC
Anticancer Drugs; 2013 Oct; 24(9):945-57. PubMed ID: 23958791
[TBL] [Abstract][Full Text] [Related]
35. Triptolide reduces proliferation and enhances apoptosis of human non-small cell lung cancer cells through PTEN by targeting miR-21.
Li X; Zang A; Jia Y; Zhang J; Fan W; Feng J; Duan M; Zhang L; Huo R; Jiao J; Zhu X
Mol Med Rep; 2016 Mar; 13(3):2763-8. PubMed ID: 26847601
[TBL] [Abstract][Full Text] [Related]
36. Synergistic combination therapy of lung cancer using paclitaxel- and triptolide-coloaded lipid-polymer hybrid nanoparticles.
Liu J; Cheng H; Han L; Qiang Z; Zhang X; Gao W; Zhao K; Song Y
Drug Des Devel Ther; 2018; 12():3199-3209. PubMed ID: 30288024
[TBL] [Abstract][Full Text] [Related]
37. Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer.
Jeong Y; Hellyer JA; Stehr H; Hoang NT; Niu X; Das M; Padda SK; Ramchandran K; Neal JW; Wakelee H; Diehn M
Clin Cancer Res; 2020 Jan; 26(1):274-281. PubMed ID: 31548347
[TBL] [Abstract][Full Text] [Related]
38. Nestin regulates cellular redox homeostasis in lung cancer through the Keap1-Nrf2 feedback loop.
Wang J; Lu Q; Cai J; Wang Y; Lai X; Qiu Y; Huang Y; Ke Q; Zhang Y; Guan Y; Wu H; Wang Y; Liu X; Shi Y; Zhang K; Wang M; Peng Xiang A
Nat Commun; 2019 Nov; 10(1):5043. PubMed ID: 31695040
[TBL] [Abstract][Full Text] [Related]
39. PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC.
Ji L; Zhang R; Chen J; Xue Q; Moghal N; Tsao MS
Sci Rep; 2019 Aug; 9(1):12437. PubMed ID: 31455821
[TBL] [Abstract][Full Text] [Related]
40. Diosmetin induces apoptosis and enhances the chemotherapeutic efficacy of paclitaxel in non-small cell lung cancer cells via Nrf2 inhibition.
Chen X; Wu Q; Chen Y; Zhang J; Li H; Yang Z; Yang Y; Deng Y; Zhang L; Liu B
Br J Pharmacol; 2019 Jun; 176(12):2079-2094. PubMed ID: 30825187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]